Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022: HLC143B | BCC Research

Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022

Published - May 2018| Analyst - BCC Research Staff| Code - HLC143B
Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022
Single User License: $5,500 Member Price: FREE

Report Highlights

The global ovarian cancer therapeutic market reached $2.1 billion in 2017. The market should reach $2.9 billion by 2022, growing at a compound annual growth rate (CAGR) of 7.1% during 2017-2022.

Report Includes

  • An overview of the global market for diagnostics and therapies for ovarian cancer, the fifth most common cancer in American women and the fourth most common cause of female cancer deaths.
  • Country specific data and analysis for United States, Canada, Germany, United Kingdom, France, Italy, Spain, India, China, Japan, and Mexico.
  • A breakdown of the markets by diagnostics and test, surgery, radiation therapy, and drug therapy.
  • Discussion of ovarian cancer biology.
  • Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
  • Evaluation of the patent landscape.
  • Comprehensive profiles of major players in the market, including Roche Holding AG, Novartis AG, Celgene Corp., and Pfizer, Inc.

 

Report Scope

This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.

The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.

The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.

Analyst Credentials

Led by Research Head Karthik Arun, the BCC Research Staff is comprised of expert analysts skilled in conducting primary research, secondary research and data analysis and who have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in microbiology, electrical engineering, business administration and surgery.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jun-2013| Analyst - Usha Nagavarapu| Code - HLC143A

Report Highlights

The global ovarian cancer drug and diagnostic market was valued at $16.1 billion in 2012. The market is predicted to grow to $18.7 billion in 2013 and $34.6 billion by 2018, a compound annual growth rate (CAGR) of 13.1% between 2013 and 2018.

Report Includes

  • An overview of the global market for diagnostics and therapies for ovarian cancer, the fifth most common cancer in American women and the fourth most common cause of female cancer deaths.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • A breakdown of the markets by diagnostics and test, surgery, radiation therapy, and drug therapy.
  • Discussion of ovarian cancer biology.
  • Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
  • Evaluation of the patent landscape.
  • Comprehensive profiles of key companies.

Want to Customize this Report?

Contact us for a confidential discussion.

781-205-2433

Custom Report
RELATED REPORTS
Share This Report